0NF3 Stock Overview
A specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Paion AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.015 |
| 52 Week High | €0.036 |
| 52 Week Low | €0.015 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -50.00% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.93% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NF3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | -0.3% |
| 1Y | -50.0% | -25.1% | 4.9% |
Return vs Industry: 0NF3 underperformed the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0NF3 underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0NF3 volatility | |
|---|---|
| 0NF3 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NF3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0NF3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 64 | Gregor Siebert | www.paion.com |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Paion AG Fundamentals Summary
| 0NF3 fundamental statistics | |
|---|---|
| Market cap | €171.21k |
| Earnings (TTM) | -€19.86m |
| Revenue (TTM) | €14.81m |
0.0x
P/S Ratio0.0x
P/E RatioIs 0NF3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NF3 income statement (TTM) | |
|---|---|
| Revenue | €14.81m |
| Cost of Revenue | €6.35m |
| Gross Profit | €8.46m |
| Other Expenses | €28.32m |
| Earnings | -€19.86m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0NF3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 20:11 |
| End of Day Share Price | 2024/12/04 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Paion AG is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Christian Ehmann | FMR - Frankfurt Main Research AG |